| Mr Tyson Tony Rothwell, MOTR/L | |
|
393 E 2nd N, Rexburg, ID 83440-1605 | |
| (208) 359-9570 | |
| (208) 359-9580 |
| Full Name | Mr Tyson Tony Rothwell |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 393 E 2nd N, Rexburg, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184166886 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT-1162 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Tyson Tony Rothwell, MOTR/L 393 E 2nd N, Rexburg, ID 83440-1605 Ph: (208) 359-9570 | Mr Tyson Tony Rothwell, MOTR/L 393 E 2nd N, Rexburg, ID 83440-1605 Ph: (208) 359-9570 |
News Archive
The EU's revised Tobacco Products Directive – which was set to place substantial new restrictions on tobacco companies' promotion of cigarettes and smokeless tobacco, including banning "e-cigarettes" – is dangerously close to stalling, and "further delay will raise serious questions about whose interest the EU Commission is promoting", according to the authors of a Comment, published in The Lancet.
Congress will consider a new drug approval pathway to encourage development of critically needed, lifesaving antibiotics as part of a strategy to address the public health crisis of antibiotic resistance. The Infectious Diseases Society of America (IDSA) proposed the new pathway, the "Special Population Limited Medical Use (SPLMU)" mechanism, to provide an important new approval option for companies interested in developing drugs to treat patients with serious infections where few or no treatment options exist.
Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg.
Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Gilenya (fingolimod) for the treatment of children and adolescents 10 to 17 years of age with relapsing remitting forms of multiple sclerosis.
› Verified 1 days ago
Bradley Saunders, OTR-L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 450 E Main St, Rexburg, ID 83440 Phone: 208-359-6532 | |
Dillon Rhet Merrill, MOTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 393 E 2nd N, Rexburg, ID 83440 Phone: 208-354-9570 | |
Karen Jannette Stewart, MOTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 36 Professional Plz Ste 110, Rexburg, ID 83440 Phone: 208-359-9570 | |
Jessica Porter Cook, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 393 E 2nd N, Rexburg, ID 83440 Phone: 208-359-9570 | |
Mr. Bryce Parker, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 99 Tamarack Ave, Rexburg, ID 83440 Phone: 208-351-3608 | |
Elizabeth David Bowman, MSOT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 36 Professional Plz Ste 110, Rexburg, ID 83440 Phone: 208-359-9570 Fax: 208-359-9580 |